Fibroblast growth factor type 23 and chronic kidney disease


A.N. Nimgirova, A.M. Esayan, I.G. Kayukov.

Department of Nephrology and Dialysis FPGE SBEI HPE FSPbSMU n.a. Acad. I.P. Pavlov of RMPH, St. Petersburg
The review discusses the role of fibroblast growth factor type 23 (FGF-23) in the progression of renal dysfunction and its cardiovascular effects in patients with chronic kidney disease. Differences in the FGF-23 effects at predialysis stage of chronic kidney disease in dialysis patients and renal allograft recipients are analyzed.

About the Autors


Information about the authors:
Nimgirova A.N. - Senior laboratory assistant at the of the Department of Nephrology and Dialysis FPGE SBEI HPE FSPbSMU n.a. Acad. I.P. Pavlov of RMPH
Esayan A.M. – MD, Professor, Head of the Department of Nephrology and Dialysis FPGE SBEI HPE FSPbSMU n.a. Acad. I.P. Pavlov of RMPH, e-mail: essaian.ashot@gmail.com
Kayukov I.G. – MD, Professor at the Department of Nephrology and Dialysis FPGE SBEI HPE FSPbSMU n.a. Acad. I.P. Pavlov of RMPH


Similar Articles


Бионика Медиа